Importantly, DNMT3A mutations in AML patients are associated with shorter overall survival (OS) and predict an improved outcome with high-dose induction chemotherapy, representing a promising prognostic and predictive tool [29,30]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.